Bringing the fundamentals into focus…
Back to Viridian Therapeutics, Inc.
How Viridian Therapeutics, Inc. stacks up
VRDN · against 340 other Healthcare companies of similar size
Overall
51/ 100
Below the middle of the pack.
Ranked #188 of 341 · scores higher than 42% of peers
Bars: peers in each 10-point band of the overall score65 peers with an overall score of 50–59, including VRDN · Click a bar to see the companies
The four scores behind it
Overall = average of valuation, growth, profitability and safety percentile (categories without data are skipped)Ranking by overall score
Top 5 and the companies ranked around VRDN| Rank | Company | Market cap | Overall | Valuation | Growth | Profitability | Risk |
|---|---|---|---|---|---|---|---|
| 1 | 3.1B EUR (≈$3.4B) | 100 | 100 | 100 | 0 / 2 | ||
| 2 | 2.1B USD | 96 | 96 | 99 | 93 | 0 / 2 | |
| 2 | 15.6B DKK (≈$2.3B) | 96 | 96 | 99 | 96 | 0 / 2 | |
| 4 | 1.5B USD | 93 | 94 | 91 | 93 | 0 / 2 | |
| 5 | 37.3B HKD (≈$4.8B) | 90 | 99 | 98 | 84 | 0 / 2 | |
| 188 | 22.0B SEK (≈$2.2B) | 51 | 58 | 71 | 60 | 2 / 2 | |
| 188 | 15.7B SEK (≈$1.6B) | 51 | 73 | 67 | 61 | 2 / 2 | |
| 188 | 1.6B USD | 51 | 55 | 61 | 47 | 1 / 2 | |
| 188 | 4.4B AUD (≈$2.9B) | 51 | 40 | 97 | 49 | 2 / 2 | |
| 188 | 2.8B USD | 51 | 8 | 99 | 7 | 0 / 2 | |
| 198 | 11.4B CNY (≈$1.6B) | 50 | 77 | 27 | 60 | 1 / 2 | |
| 198 | 2.9B USD | 50 | 57 | 75 | 66 | 2 / 2 | |
| 198 | 2.7B USD | 50 | 8 | 92 | 14 | 0 / 2 | |
| 198 | 5.3B USD | 50 | 45 | 66 | 31 | 1 / 2 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score